Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Teva & Blackstone Team Up to Accelerate Duvakitug for UC & CD: Phase‑III Success Sparks New IBD Treatment Horizon

Teva and Blackstone’s new partnership pushes duvakitug, a selective IL‑23 inhibitor, toward a fast‑track FDA/EMA review—offering potent UC/CD remission with a strong safety profile and new growth prospects for IBD biologics.

Dr. Michael Chen

05/03/2026, 23:32

5 minutes to read

How Natera’s Signatera® MRD Test Could Revolutionize Bladder‑Preservation Strategies at ASCO

Discover how Natera’s Signatera ctDNA test is reshaping bladder‑cancer care with MRD‑guided therapy, market insights, and ASCO presentation highlights.

Dr. Michael Chen

05/03/2026, 08:56

5 minutes to read

Royalty Pharma Expands Asia Presence, Secures $250M Zymeworks Note, Boosts Growth

Royalty Pharma expands into Asia and secures a $250 M royalty‑backed note with Zymeworks to fund late‑stage antibody trials, boosting growth while preserving equity.

Dr. Michael Chen

04/03/2026, 08:57

5 minutes to read

Amgen Shares Surge as New CRISPR and ADC Therapies Boost Analyst Optimism

Amgen’s stock rises as breakthrough CRISPR‑CAR‑T for pancreatic cancer and an ADC for CKD gain FDA designations, promising new revenue streams and investor confidence.

Dr. Michael Chen

02/03/2026, 17:17

4 minutes to read

How Natera’s 2025 Earnings and Signatera MRD Data Drive Precision Oncology Growth

Explore Natera Inc.’s 2025 earnings and breakthrough Signatera MRD platform—showing 18% revenue growth, 42% gross margin, and clinical data that could shape personalized cancer treatment and reimbursement approvals.

Dr. Michael Chen

01/03/2026, 20:19

4 minutes to read

Amgen Shares Rebound as Analyst Upgrades Boost Pipeline Confidence

Amgen’s stock rebounds as analyst upgrades and a robust therapy pipeline—including CAR‑T and kinase inhibitors—boost investor confidence and signal strong growth prospects.

Dr. Michael Chen

01/03/2026, 18:40

3 minutes to read

Grifols 2025 Earnings Surge, 2026 Outlook Promises 25%+ Operating Profit Growth

Grifols SA’s 2025 results show robust profit growth and debt cut, with a 2026 outlook targeting 25 % operating profit rise driven by new plasma‑derived therapies and regulatory approvals.

Dr. Michael Chen

01/03/2026, 15:22

5 minutes to read

Johnson & Johnson Unveils Pasritamig‑Docetaxel for Prostate Cancer & New Aspiration Catheters in 2026 Update

Johnson & Johnson’s latest 2026 report reveals early promise for pasritamig + docetaxel in advanced prostate cancer and launches new, infection‑reduced aspiration catheters, boosting both drug and device portfolios.

Dr. Michael Chen

28/02/2026, 17:15

5 minutes to read

Dupixent Wins EU Recommendation for Treating Children 2–11 with Chronic Urticaria

Dupixent’s new EU pediatric CSU indication, backed by LIBERTY‑CUPID trials, promises first‑of‑its‑kind targeted relief for 2‑11‑year‑olds, boosting Regeneron’s market reach and patient care.

Dr. Michael Chen

28/02/2026, 11:28

3 minutes to read

Amgen Shares Steady as New Biologics Show Early Success – Investors Eye Phase 3 Outlook

Amgen’s steady share price, backed by solid earnings and promising biotech pipeline, shows potential upside as Phase 3 data for AMG 301, AMG 701, and AMG 510 emerge.

Dr. Michael Chen

28/02/2026, 08:20

5 minutes to read

Older articles